Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Apexigen Inc (APGN)
| -43.5 | -10.5 | -28.2 | -92.2 | -- | -- | -- |
|
BSE Sensex*
| -13.1 | -5.5 | -6.7 | -10.5 | 5.2 | 7.1 | 10.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Apexigen Inc (APGN)
Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical... development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California. As of August 23, 2023, Apexigen, Inc. operates as a subsidiary of Pyxis Oncology, Inc.. Read more
-
Pres, CEO & Director
Dr. Xiaodong Yang M.D., Ph.D.
-
Pres, CEO & Director
Dr. Xiaodong Yang M.D., Ph.D.
-
Headquarters
San Carlos, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Apexigen Inc (APGN)
What is the current share price of Apexigen Inc (APGN) Today?
The share price of Apexigen Inc (APGN) is $0.39 (NASDAQ) as of 01-Sep-2023 09:30 EDT. Apexigen Inc (APGN) has given a return of -92.19% in the last 1 years.
What is the current PB & PE ratio of Apexigen Inc (APGN)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.43
|
2.14
|
|
2021
|
-6.24
|
-1.32
|
|
2020
|
--
|
--
|
|
2022
|
-0.43
|
2.14
|
|
2021
|
-6.24
|
-1.32
|
What is the 52 Week High and Low of Apexigen Inc (APGN)?
The 52-week high and low of Apexigen Inc (APGN) are Rs -- and Rs -- as of 08-Jun-2026.
What is the market cap of Apexigen Inc (APGN)?
Apexigen Inc (APGN) has a market capitalisation of $ 10 Mln as on 01-Sep-2023. As per SEBI classification, it is a company.
Should I invest in Apexigen Inc (APGN)?
Before investing in Apexigen Inc (APGN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.